Browse the evidence

Semaglutide 2.4 mg subcutaneous once weekly significantly reduces body weight and improves cardiovascular risk factors in obese or overweight adults with or without type 2 diabetes.

Semaglutide 2.4 mg injected once weekly, combined with a low-calorie diet and exercise, is a highly effective treatment for weight loss and cardiovascular risk reduction in obese or overweight adults. You must commit to long-term use, as stopping the medication leads to weight regain. Start with a lower dose to minimize stomach side effects, which usually improve over time.

Concomitant administration of ixekizumab (IL-17A inhibitor) and tirzepatide (dual GIP/GLP-1 receptor agonist) achieves significantly greater disease control and weight loss in adults with psoriatic arthritis (PsA) and overweight/obesity compared to ixekizumab monotherapy.

For PsA patients who are overweight or obese, adding tirzepatide to ixekizumab therapy offers a dual benefit: significantly better joint symptom control and substantial weight loss, compared to using ixekizumab alone. This combination addresses both the inflammatory and metabolic aspects of the disease, leading to improved physical function and quality of life, with a safety profile consistent with the individual drugs.

Short sleep duration (less than 5 hours per night) is significantly associated with an increased risk of obesity, with an odds ratio of 1.89 in children and 1.55 in adults.

Aim for 7-8 hours of sleep per night. Sleeping less than 5 hours significantly increases your risk of obesity. Prioritize sleep as a key component of your metabolic health strategy.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior weight loss (up to 20.9%) and visceral fat reduction compared to other anti-obesity medications.

Tirzepatide is currently the most effective pharmacological tool for significant weight loss, capable of reducing body weight by over 20% in clinical trials. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and fat storage. While highly effective, it requires weekly injections and careful monitoring for gastrointestinal side effects like nausea.

Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.

Semaglutide 2.4 mg, taken as a weekly injection, is a highly effective treatment for obesity, leading to an average 14.9% weight loss over 68 weeks. It works by mimicking the GLP-1 hormone to increase satiety and reduce appetite. Common side effects include gastrointestinal issues like nausea and diarrhea.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) is recommended for individuals with BMI > 35 kg/m² regardless of comorbidities, and for those with BMI 30-34.9 kg/m² and metabolic diseases.

Bariatric surgery is now recommended for individuals with a BMI over 35, even without other health issues, and for those with a BMI of 30-34.9 who have metabolic diseases. Procedures like Roux-en-Y gastric bypass and sleeve gastrectomy provide substantial long-term weight loss and improve quality of life.

Obesity is a major independent risk factor for the development of coronary artery disease, heart failure, atrial fibrillation, and sudden cardiac death, with risk increasing linearly with BMI and visceral adiposity.

If you have excess body fat, especially around your midsection, your risk for heart disease, heart failure, and arrhythmias increases significantly, even if your blood pressure and cholesterol are normal. Do not rely on BMI alone; ask your doctor about assessing visceral fat or using waist circumference, as these are better predictors of heart risk.

Every 5 kg of weight loss from anti-obesity treatment reduces the risk of myocardial infarction, stroke, and heart failure.

Losing just 5 kg (about 11 lbs) through anti-obesity treatments can significantly lower your risk of heart attack, stroke, and heart failure. This highlights the importance of achieving even modest weight loss for long-term cardiovascular health. Work with your healthcare provider to find a safe and effective weight management strategy.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.

Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.

Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.

If you are struggling to lose weight with Semaglutide, ask your doctor about Tirzepatide. Clinical trials show it can lead to greater weight loss (around 21%) compared to Semaglutide (around 14%) in obese patients without diabetes. However, be aware that it may be more expensive and less likely to be covered by insurance.

Weight loss of 7-10% is required to resolve steatohepatitis (MASH) and regress fibrosis, whereas 5% loss primarily improves steatosis.

To reverse liver inflammation, aim for a 7-10% total body weight loss through diet and exercise. Losing 5% helps reduce liver fat, but hitting the higher threshold is necessary to fix the actual liver damage (inflammation). Combine caloric restriction with both aerobic and resistance training to preserve muscle mass.

The physiological mechanism of diabetes remission via weight loss involves the reduction of ectopic fat in the liver and pancreas, which restores beta-cell function and insulin sensitivity.

N/A (Mechanistic explanation).

GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.

Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.

Tirzepatide is a once-weekly injection approved for T2DM and obesity. It works by mimicking hormones that regulate blood sugar and appetite. Clinical trials show it lowers HbA1c by up to 2.5% and causes significant weight loss (15-25%). It is more effective than semaglutide and insulin for these metrics. Common side effects are gastrointestinal (nausea, diarrhea) but often improve over time. Weight regain is common if the drug is stopped, suggesting long-term use may be necessary for sustained results.

Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.

If your primary goal is maximum weight loss and you do not have diabetes, tirzepatide (15mg weekly) is clinically superior to semaglutide (2.4mg weekly). While both are effective, tirzepatide yields significantly greater fat loss and waist reduction. Be aware that while tirzepatide may have better GI tolerability, it still carries class-specific risks.

Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.

If you stop taking incretin-based weight loss medication, you will likely regain about two-thirds of the weight you lost within a year. This is not a failure of willpower but a biological response to the loss of the drug's hormonal effects. To maintain your weight loss, you likely need to continue the medication long-term or use very aggressive, sustained lifestyle interventions, though even those are often insufficient to prevent significant regain.

GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.

GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.

mTORC1 is the central integrator of anabolic signals from both resistance exercise and dietary protein, mediating muscle protein synthesis and hypertrophy.

Understanding mTORC1 is important for researchers but has limited direct practical application for the average person. Focus on the external drivers: lift weights and eat enough protein.

Lifestyle interventions (weight loss, diet, exercise) are key to treating diabetic dyslipidemia and can significantly reduce the incidence of Type 2 Diabetes in prediabetic individuals.

Losing a modest amount of weight (6-8%) and exercising regularly (2 hours/week) can cut your risk of developing Type 2 Diabetes by more than half. It also improves your heart health and reduces the need for other medications. Start with small, sustainable changes.

Intensive lifestyle interventions (diet, physical activity, weight management) reduce the risk of progression from prediabetes to type 2 diabetes by 42-58% and improve long-term cardiovascular outcomes.

Start with a 6-month intensive lifestyle program focusing on losing 5-10% of your body weight and getting at least 150 minutes of moderate exercise (like brisk walking) per week. Combine this with dietary changes and smoking cessation if applicable. Follow up with your healthcare provider after 3 months to assess progress and adjust your plan. This is the most effective first step to prevent progression to type 2 diabetes.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by 31% and is recommended for specific high-risk subgroups (age 25-59, BMI ≥35, FPG ≥6.1 mmol/L, or history of gestational diabetes).

If lifestyle changes alone are not enough, your doctor may prescribe metformin. It is typically started at a low dose (500 mg) and increased to 1,500 mg daily to minimize stomach issues. Use the extended-release version if possible. Monitor your blood sugar every 6 months. This is particularly recommended if you are younger, have a higher BMI, or have a history of gestational diabetes.

Second-generation obesity management medications (semaglutide and tirzepatide) produce 15-20% body weight loss, significantly exceeding the 5-10% typically achieved by lifestyle interventions alone.

Second-generation obesity medications like semaglutide and tirzepatide are significantly more effective for weight loss than lifestyle changes alone, achieving 15-20% body weight reduction. They work by targeting hormonal pathways that regulate appetite and metabolism, addressing the biological drivers of obesity rather than relying solely on willpower.

Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.

Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.

Metformin and behavioral interventions produce beneficial weight loss in persons with serious mental illness (SMI), with high-strength evidence for both.

If you have a serious mental illness and are struggling with weight, combining metformin with behavioral lifestyle changes is a highly effective, evidence-based strategy. This approach directly addresses the metabolic risks that contribute to premature mortality in this population.